I agree with the authors that a weakness of the study is the lack of pharmacy data for the subjects. While the authors discuss the possible effect of allopurinol on colorectal cancer incidence among gout patients, they do not mention the possible effects of colchicine or aspirin, both of which have been proposed to have anticancer effects based on previous studies. Introduction and Discussion: the authors put a lot of emphasis on possible cellular mechanisms, which may play a role in the association between gout, allopurinol and CRC. In light of the null result, I suggest to put much less emphasis on this background information and to shorten the paper, as it turns out that these explanations seem to be of little relevance given that there is no association overall.
Introduction: the authors acknowledge that metabolic syndrome is a risk factor for CRC, and they state that they have no information on this parameter. In addition, information on BMI, smoking and alcohol is lacking too. These are all risk factors for gout too and fulfill the criteria of confounding. Even though you acknowledge this limitation, you could discuss the impact of missing data on the analysis in more detail in the Discussion.
Study cohort and Results: the gout group and the non-gout control group differ with regard to many parameters. Why did you not try to run a propensity-score analysis, which would balance the differences between the two cohorts to some degree? Discussion: you emphasize the barely statistically significant finding of a RR of 1.15 (95% CI 1.04-1.26). You then state that after adjusting for diabetes, hypertension and hyperlipidemia, the result is no longer statistically significant. In fact, the entire weakly increased RR is completely gone after adjusting, so that the findings are a clear null result. Please put more emphasis on this fact in the interpretation of the findings, including also in the abstract.
REVIEWER
Matthew Grainge University of Nottingham, United Kingdom REVIEW RETURNED 06-Apr-2019
GENERAL COMMENTS
In this paper Chuang and colleagues set out to explore evidence of an independent association between gout and the development of CRC. No association was observed once potential confounders were taken into account. However, as the authors state this research potentially opens up future work to explore the degree to which allopurinol use in gout patients could increase or decrease the risk of specific cancers. There are several areas which need attention.
Introduction: Overall this could be improved to more fully justify the need for the present study. Four papers (refs. 20, 21, 22 and 26) were cited which seem to directly address this question, however, one of these (ref. 26) is of a randomised trial of allopurinol in people with CRC adenoma so does not provide a cohort comparison as claimed. Please provide a more complete overview of the studies which have provided data on the relationship between gout and the development of CRC and other cancers. From this, deficiencies with existing studies and/or gaps in the research evidence should be clearly highlighted to justify the need for the present study.
Methods>Data sources: More justification is needed that use of major illness/injury certificates will ensure accurate diagnoses (citing external justification for this if possible). In the strengths/limitations section, it is justified that a major illness/injury certificate will only be issued after malignancy diagnosis is confirmed. This will re-assure against a high level of false positive diagnoses but what about false negatives (missed cases)?
Methods>Study cohort: A more systematic approach to the identification of and adjustment for confounders was expected. The need to address unmeasured or unknown confounders was recognised but then only a small number (n=3) of pre-existing conditions were adjusted for. Were this chosen on the basis of availability of data or a priori evidence that these conditions could exert a confounding effect on this association? Could calculation of a comorbidity score have been done instead to enable more complete control for confounding by co-morbidities in a single variable?
Methods>Statistical analysis: Please state explicitly which variables were controlled for in the adjusted analyses (this can only be partly determined from the previous section). For instance, it is important to highlight that age was adjusted for (only mentioned in Discussion) as the imbalance in average age of the gout patients and control group, possibly through use of broad 5year bands when matching, is large enough to potentially influence findings.
Results>Characteristics of participants: An explanation of the potential reasons for the slightly larger average duration of followup in cases should be provided.
Results>relative risks (p. 11, line 38): Please reword the final part of this sentence to be more specific about what you mean, i.e. The difference in the incidence of gout between gout patients and controls was not statistically significant for any of the 4 age categories. For similar reasons, please reword the title of table 2 to "IRR comparing the risk of gout between gout and control groups".
Results>Relative risks (p.11, 2nd para.): The confounders adjusted for should be listed in the footnote for table 3 (refer to earlier comment).
Results>Relative risks (p.11, 2nd para.): Overall I found the text in this paragraph and table 3 difficult to interpret. My understanding is that interpretation has now flipped and that for the covariates you are now presenting the risk of CRC on the basis of that covariate (adjusted for gout and other terms?) rather than using them to define subgroups within which the main gout/CRC association was explored. This needs to be made more explicit in the text (either methods or results). Also, in table 3 if gout was listed in the rows in the same way as for the other covariates (rather than providing data for the columns) this would also make this clearer.
Discussion>page 17, line 15: Ref. 38 is claimed to provide valuable data on lower rates of CRC in users of allopurinol, however, the reference provided is from a book chapter rather than research paper, the topic of which seems only vaguely related to this study question. It would be helpful to provide alternative details as to where the data from this study from Israel can be obtained.
Discussion>General: Whilst recognition of unmeasured confounding was present in the strengths/limitations paragraph more discussion on the likely impact on the results should be provided. Which variables in the view of the authors are most likely to confound (or provide an alternative explanation for) a relationship between gout and CRC. Were these the variables adjusted for as a consequence of an a priori approach to confounder selection or were these factors which could not be adjusted for as data were not available?
Discussion>General: As the authors indicate, this research opens up a potentially more important research question than the one addressed by this study, that being whether allopurinol may influence cancer risks, and the extent to which this risk varies for different cancers. The discussion on this could be improved by more fully providing; 1. A more complete overview of current data from cohort studies and RCTs on this topic. 2. A brief overview of key aspects to consider in the design of future studies on this topic.
General: Whilst the manuscript was clearly legible, the standard of written English could be improved in places. I would advise a complete proof reading of the manuscript so that the standard is acceptable for an English language journal. An example is in line 18 of page 16…"gout patients are more prevalent in rural area than non-gout group".
VERSION 1 -AUTHOR RESPONSE
patients and 84,248 matched non-gout controls from Taiwan national health insurance research database. The authors concluded that there was no significant association between gout an CRC risk. Comment 1. How many gout patients did develop to CRC 1-2 years after diagnosis of gout? A sensitivity analysis after excluding these cases would be suggested. Response: We have followed the Reviewer's suggesting by excluding the CRC incident cases who developed in the first 2 years during the follow-up from analysis. The sensitivity analysis considered 130 gout patients and 334 controls who developed CRC in the first 2 years to be censored on date of CRC first-time diagnosis. After exclusion, 443 gout patients and 1346 control patients developed CRC were re-analyzed, and the corresponding covariate adjusted HR was estimated at 1.05 (95% CI, 0.94-1.17). We have summarized the results from the above sensitivity analysis in the revised manuscript (page 10, lines 21-22; page 11, line1-2). "In the sensitivity analysis, which excluded 130 patients with gout and 334 controls who developed CRC in the first two years, 443 patients with gout and 1346 control patients who developed CRC were re-analysed. The covariate adjusted HR was estimated at 1.05 (95% CI: 0.94-1.17) in the reanalysis." Comment 2. page 7, Study cohort: It is not exact 1:3 matched analysis (28,061 vs. 84,248); please make a clear description. Also, please present the final number of gout patients and non-gout controls included in this study in the Study Cohort section. Response: We checked the cohort selection process and noted that we initially used a matching ratio of 1:4 in selecting gout (n=28,061) and non-gout (n=112,244) subjects. Totally 27,996 non-gout subjects who had a prior diagnosis of all-cancer were then deleted, leaving 84,248 non-gout subjects in the current analysis.
We have provided the above information in both the Study Cohort section (page 7, lines 1-5) and Figure 1 .. Comment 3. Please mention all the confounding factors adjusted in Tables 2 and 3 in both Text and  Tables (as footnote) . Response: As suggested, text shown in Statistical analysis and Table 3 footnote is updated. "We used the Cox proportional hazards model with adjustment for age, sex, urbanisation, hypertension, diabetes, hyperlipidaemia, CCI, and PS to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Adjustment for age was mainly due to imbalance in average age between study groups, possibly through use of broad 5-year bands when matching." (page 7, line 23 to page 8,
Reviewer: 2 Reviewer Name: Anastasia Slobodnick Institution and Country: New York University School of Medicine, USA Please state any competing interests or state 'None declared': None
Please leave your comments for the authors below This is an interesting and relevant study evaluating colorectal cancer incidence in patients newly diagnosed with gout between 2000 and 2010 in Taiwan. A strength of this study is that all subjects with colorectal cancer were required to have pathology for the purposes of insurance in Taiwan, so all of the cancer diagnoses have been confirmed.
Comment 1. I agree with the authors that a weakness of the study is the lack of pharmacy data for the subjects. While the authors discuss the possible effect of allopurinol on colorectal cancer incidence among gout patients, they do not mention the possible effects of colchicine or aspirin, both of which have been proposed to have anticancer effects based on previous studies.
Response: The authors are grateful for the comments. Colchine is a commonly used antiinflammatory agent in patients with acute gouty arthritis attack, while aspirin is not suggested for gout patients. Aspirin and other salicylates are in fact anti-uricosuric. Taking aspirin or other salicylates can increase plasma uric acid levels and increase the risk of gout. Aspirin and other salicylates can also interfere with the action of uricosuric drugs prescribed for the treatment of gout. Thus, aspirin is not recommended for anti-inflammatory treatment in gout patients. We do concur with the reviewer's suggestion that colchicine use could be a potential confounder for the relationship between gout and CRC incidence, and as suggested, we have added the following information to the Discussion section: "One possible explanation for the minimal increase in CRC risk among patients with gout is the potential protective effect of allopurinol and colchicine use for patients with gout." (page 16, lines 9-11) " Over a century, colchicine has been used for treatment and prevention of acute gouty arthritis attack due to its various mechanisms 42 43 . Colchicine interferes with microtubule growth and dramatically abrogates the inflammatory response to urate crystal stimulation in humans 44 . In addition to its antiinflammatory effect, colchicine has been reported for its anticancer effect in vitro and in animal models 45 46 . In a 12-year cohort study, colchicine use was associated with a significantly low risk of prostate cancer and CRC in male Taiwanese patients with gout. Further pharmaco-epidemiological studies should be conducted to specifically examine the relationship between colchicine use and CRC risk." (page 17, lines 12-19)
Reviewer: 3 Reviewer Name: Christoph Meier Institution and Country: University of Basel -Switzerland Please state any competing interests or state 'None declared': None
Please leave your comments for the authors below The authors of this large observational study from Taiwan assessed the association between gout and the risk of developing colorectal cancer (CRC). The methodology is straightforward and seems to be OK. However, I do have several points of criticism:
Comment 1. The authors explain that allopurinol might have anti-cancer effects, which could have counterbalanced an elevated CRC-risk in gout patients. They announce a future study in which they will consider allopurinol use in the analysis. Do you have data on allopurinol? Why did you not include this information in this analysis and report one full analysis, covering all aspects of interest and answering all study questions? Response : We have followed the Reviewer's suggestion by further comparing the risk of CRC between gout patients with and without prescriptions for allopurinol during 1997 and 2013. The analytical results (shown below) indicated a weakly but insignificantly inverse association between allopurinol and risk of CRC among gout patients (HR, 0.95; 95%, 0.80-1.12). Despite that, we are unable to entirely exclude the possibility that allopurinol could be responsible for the null association between gout and CRC, mainly because we are unable to take into account a comprehensive list of risk factors for CRC in the analysis. We have summarized the above information in the Discussion section. (page 17, lines 1-10) "To further explore the relationship between allopurinol and CRC risk, we conducted a posterior analysis comparing CRC risk between patients with gout with and without prescriptions for allopurinol in 1997 and 2013. Follow-up from patients with gout and taking allopurinol started from date of allopurinol prescription, whereas follow-up of those without allopurinol medication started on the date of gout diagnosis. Analytical results indicated a weak and insignificantly inverse association between allopurinol and risk of CRC among patients with gout (HR: 0.95; CI 95%: 0.80-1.12). This posterior analysis failed to entirely exclude the possibility that allopurinol could be responsible for the null association between gout and CRC, mainly because we are unable to consider a comprehensive list of risk factors for CRC in the analysis." (page 17, lines 1-10) Comment 2. Introduction and Discussion: the authors put a lot of emphasis on possible cellular mechanisms, which may play a role in the association between gout, allopurinol and CRC. In light of the null result, I suggest to put much less emphasis on this background information and to shorten the paper, as it turns out that these explanations seem to be of little relevance given that there is no association overall. Response: As suggested, the revised Introduction is updated and we have deleted the following paragraph that appeared in our initial submission "Gout attacks can occur quickly, recovering over time, and slowly injuring the tissues of the inflammatory area. In previous studies, several inflammation genes including the tumor necrosis factor-α gene 9 , Interleukin-6 10 , and transforming growth factor-β1 gene 11 are involved in gout development. In recent years, it is well-documented that NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome in macrophages after MSU activation plays the central role of gout inflammation 12 13 . The NLRP3 inflammasome is a multiprotein complex contains NLRP3(NACHT, LRR, PYD domains-containing protein 3), ASC (Apoptosis-associated speck-like protein containing a caspase recruitment domain) and a zymogen, procaspase-1. Once NLRP3 inflammasome is activated in response of initial inflammatory signal, it can then carry out inflammatory cascades including auto-cleavage of inactive procaspase-1into an active cysteine protease enzyme, caspase-1, and result in proteolytic cleavage of pro-IL-1B at Asp116 into IL1β, cleavage of pro-IL-18 into IL-18 to induce IFN-γ secretion and induces pyroptosis, which are involved in various immunological reactions such as proliferation, activation, and recruitment of additional inflammatory cells [14] [15] [16] ." Comment 3. Introduction: the authors acknowledge that metabolic syndrome is a risk factor for CRC, and they state that they have no information on this parameter. In addition, information on BMI, smoking and alcohol is lacking too. These are all risk factors for gout too and fulfill the criteria of confounding. Even though you acknowledge this limitation, you could discuss the impact of missing data on the analysis in more detail in the Discussion. Response: As suggested, the Discussion section is updated and we have added the following paragraph. "In the Framingham study, a high BMI has been observed in patients with gout 23. In addition to obesity, life style factors, including alcohol intake and smoking, were prevalent in the gout group 24-26. Associations between these factors and CRC have been well documented in epidemiological studies 27 28. However, the NHI claims data provide no information on smoking habits, alcohol consumption and BMI. Failure to adjust these risk factors may have resulted in residual confounding in our study results." (page 15, lines 14-20) Comment 4. Study cohort and Results: the gout group and the non-gout control group differ with regard to many parameters. Why did you not try to run a propensity-score analysis, which would balance the differences between the two cohorts to some degree? Response: Honestly, it would be extremely, even not impossible, difficult for us to re-select the control subjects by propensity score (PS) matching method from the entire beneficiaries of Taiwan's National Health Insurance program in 2000. The difficulties are involved in issues of not only finance but also feasibility. Specifically, if we choose to re-sample the control subjects, we have to re-write and resubmit our research protocol to the National Health Research Institutes (NHRI) for approval. Once the application being approved, the NHRI will charge us again for the new datasets; and we believe our research grant won't be able to cover such additional expenses, that could be a lot. Alternatively, we calculated, using all variables listed in Table 1 , the PS in predicting a gout diagnosis for each of the study subjects. The distributions of PS for gout and non-gout groups are shown below:
Gout group
Non-gout group
Although both groups showed similar patterns in PS distribution, patients with gout apparently had greater PS scores then the non-gout controls (Mean/SD: 0.31/0.14 vs 0.23/0.11). The proportion of gout patients with a PS score >0.3 was much higher than that of non-gout controls (46.52% vs 20.27%), which would make it very unlikely to get enough non-gout controls with higher PS scores if PS matching method is performed. Besides, the sample size would be substantially reduced if we manage to perform PS matching method in re-selecting the non-gout controls based on our current dataset. Because the incidence of CRC is considered low, and the strength of association, if any, between gout and CRC is expected to be weak, a great reduction of sample size would definitely compromise the statistical power of the analysis.
We, after consideration, decide to use adjustment of PS in the regression model as alternative to solve the potential problem of residual confounding. In fact, it has been documented that in most studies in the literature, the effect estimates from multivariate regression models were quite close to the effect estimates derived from various implementations of the propensity score including matching and adjustment, as long as the number of outcome events was much larger than the number of potential confounders (Cepeda et al., 2003; Braitman and Rosenbaum, 2002; Sturmer et al., 2005; Shah et al., 2005) . We consider this additional analysis as a sensitivity analysis used to examine the robustness of our initial findings.
We did re-analyses with adjusting continuous PS in the Cox regression model, and compared the results with the data from multivariate regression models with adjusting individual co-morbidity. The comparison was shown below: Table shows essentially the same HR estimated from the multivariate regression models with adjustment for various covariates and the models with further adjustment for PS. Because of the similarity in results, we presented the results from the multivariate Cox regression models with adjustment for covariates and PS simultaneously, and summarized the above information as a sensitivity analysis in the revised manuscript. We have also included the following text in the Method and Result section, respectively. In Statistical Analysis section: " In addition, although we managed to adjust for potential risk factors for CRC, certain lifestyle factors, such as smoking, overweight and physical activities, remained unadjusted in the analysis mainly due to lack of such data in medical claims. By using all variables listed in Table 1 , we calculated the propensity score (PS) in prediction of gout diagnosis for each of the study subjects to minimise potential confounding by unmeasured confounders. We then conducted sensitivity analysis by treating PS and CCI score as covariates in the Cox model to assess the robustness of HR estimated from multivariate regression analysis.." (page 8, lines 8-15) In Risk and relative risk of CRC section: " Once the Cox regression model additionally considered PS in addition to covariates listed in Table 1 , it showed HR of 1.04 (95% CI: 0.95-1.15) for the gout group (Table 3) . This finding coincided with the results estimated from the model without adjusting for PS (HR, 1.03; 95% CI: 0.93-1.14)." (page 10, lines 18-21) References: Comment 5. Discussion: you emphasize the barely statistically significant finding of a RR of 1.15 (95% CI 1.04-1.26). You then state that after adjusting for diabetes, hypertension and hyperlipidemia, the result is no longer statistically significant. In fact, the entire weakly increased RR is completely gone after adjusting, so that the findings are a clear null result. Please put more emphasis on this fact in the interpretation of the findings, including also in the abstract. Response: As suggested, the Risk and relative risk of CRC section is updated by adding the following paragraph: "Although a higher CRC IRR (1.15) was observed in the gout cohort than in the non-gout cohort, the adverse effect of gout on CRC risk disappeared after potential confounders, including age, sex, residential location and urbanisation status, hypertension, diabetes, hyperlipidaemia, comorbidity score and PS, were considered and adjusted in the multivariate regression model." (page 10, lines 12-16) Reviewer: 4 Reviewer Name: Matthew Grainge Institution and Country: University of Nottingham, United Kingdom Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below In this paper Chuang and colleagues set out to explore evidence of an independent association between gout and the development of CRC. No association was observed once potential confounders were taken into account. However, as the authors state this research potentially opens up future work to explore the degree to which allopurinol use in gout patients could increase or decrease the risk of specific cancers. There are several areas which need attention. Comment 1. Introduction: Overall this could be improved to more fully justify the need for the present study. Four papers (refs. 20, 21, 22 and 26) were cited which seem to directly address this question, however, one of these (ref. 26) is of a randomised trial of allopurinol in people with CRC adenoma so does not provide a cohort comparison as claimed. Please provide a more complete overview of the studies which have provided data on the relationship between gout and the development of CRC and other cancers. From this, deficiencies with existing studies and/or gaps in the research evidence should be clearly highlighted to justify the need for the present study. Response: As suggested, Ref 26 (Puntoni M, et al. A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma. Cancer Prev Res (Phila) 2013;6(2):74-81.) has been deleted, and the literature review has been updated substantially in the Introduction Section to justify the need for the present study. Comment 2. Methods>Data sources: More justification is needed that use of major illness/injury certificates will ensure accurate diagnoses (citing external justification for this if possible). In the strengths/limitations section, it is justified that a major illness/injury certificate will only be issued after malignancy diagnosis is confirmed. This will re-assure against a high level of false positive diagnoses but what about false negatives (missed cases)?
Response: We are very thankful the inspired comments. It is unfortunate, however, there is no relevant reference available concerning the sensitivity and specificity of using major illness/injury certificates to determine cancer. We have included this comment in the Strengths and Limitation section: "The potential bias arising from such potential disease misclassification would be minimal mainly because cancer diagnosis appearing in Taiwan's NHI claims should be accompanied by a major illness/injury certificate, which can be issued only after malignancy diagnosis is pathologically confirmed. Moreover, the chance of false negative is believed to be very low, similar to that of Taiwan major illness/injury certificate issued by oncologists. This certificate can be used to waive co-payment by patients for cancer treatment, which is an essential patient right." (page 14, lines 10-16) Comment 3. Methods>Study cohort: A more systematic approach to the identification of and adjustment for confounders was expected. The need to address unmeasured or unknown confounders was recognised but then only a small number (n=3) of pre-existing conditions were adjusted for. Were this chosen on the basis of availability of data or a priori evidence that these conditions could exert a confounding effect on this association? Could calculation of a comorbidity score have been done instead to enable more complete control for confounding by co-morbidities in a single variable? Response: In Introduction section, we have stated "To our knowledge, metabolic syndromes, including obesity, hypertension, diabetes mellitus and dyslipidaemia, are highly associated with gout development ". (page 5, lines 17-18) And, we have followed the Reviewer's comment by including the descriptions of why the 3 diseases (i.e., hypertension, diabetes, and hyperlipidemia) were analyzed in our study " Under the concern of possible unmeasured confounders, we identified baseline metabolic and anthropometric traits of metabolic syndrome, including hypertension (ICD-9-CM 401-405), diabetes mellitus (ICD-9-CM 250) and hyperlipidaemia (ICD-9-CM 272), which have been closely associated with CRC development 16, 17 ". (page 7, lines 7-11). Additionally, we have followed the Reviewer's comments by calculating the Charlson Comorbidity Index score for each study subject, and adjusting this comorbidity score in the multivariate Cox regression model. (Please see the Revised Tables 1 and 3) "Additionally, we calculated the Charlson comorbidity index (CCI) score, a weighted summary measure of clinically important concomitant diseases adopted for use with ICD-9-CM-coded administrative databases 19, 20 for each study subject." (page 7, lines 11-14) Comment 4. Methods>Statistical analysis: Please state explicitly which variables were controlled for in the adjusted analyses (this can only be partly determined from the previous section). For instance, it is important to highlight that age was adjusted for (only mentioned in Discussion) as the imbalance in average age of the gout patients and control group, possibly through use of broad 5-year bands when matching, is large enough to potentially influence findings. Response: As suggested, text in Statistical analysis and footnote of Table 3 is updated. "We used the Cox proportional hazards model with adjustment for age, sex, urbanisation, hypertension, diabetes, hyperlipidaemia, CCI, and PS to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Adjustment for age was mainly due to imbalance in average age between study groups, possibly through use of broad 5-year bands when matching." (page 7, line 23 to page 8, line 4) Comment 5. Results>Characteristics of participants: An explanation of the potential reasons for the slightly larger average duration of follow-up in cases should be provided. Response: Our data showed a shorter mean follow-up in gout group than in non-gout group (8.4±3.5 vs 9.4±3.7 years). This slight difference could be due to a higher proportion of study subjects who encountered the event of interest (i.e., colorectal cancer) (573/28061=2.04% vs 1680/84248=1.98%). An incident colorectal cancer observed during the follow-up would lead to termination of follow-up. Nonetheless, the mean follow-up between the two groups was not statistically significant. We have therefore included the following text in the revised Characteristics of the study participants. "Mean follow-up was slightly but insignificantly (p>0.05) shorter in the gout group than in the non-gout group (8.4±3.5 versus 9.4±3.7 years). This result could be due to the slightly greater proportion of patients with gout terminating their follow-up at an earlier time because of CRC incidence.". (page 8, line 23 to page 9, line3) Comment 6. Results>relative risks (p. 11, line 38): Please reword the final part of this sentence to be more specific about what you mean, i.e. The difference in the incidence of gout between gout patients and controls was not statistically significant for any of the 4 age categories. For similar reasons, please reword the title of table 2 to "IRR comparing the risk of gout between gout and control groups". Response: We have followed the Reviewer's comment by revising the last sentences of the Risk and relative risk of CRC section. "For both gout and non-gout cohorts, the incidence density of CRC was highest in the oldest group at 4.76 versus 4.31 per 1,000 person-years, respectively. The IRRs comparing the risk of gout between the gout and control groups were all elevated but insignificant for all the four age groups." (page 10, lines 8-11) In addition, we have also revised the title of Table 2 as "IRR comparing the risk of gout between the gout and control groups.". Please see the revised Table 2 (page 11) Comment 7. Results>Relative risks (p.11, 2nd para.): The confounders adjusted for should be listed in the footnote for table 3 (refer to earlier comment). Response: As suggested, the covariates adjusted in the Cox model have been listed at the footnote of Table 3 . Comment 8. Results>Relative risks (p.11, 2nd para.): Overall I found the text in this paragraph and table 3 difficult to interpret. My understanding is that interpretation has now flipped and that for the covariates you are now presenting the risk of CRC on the basis of that covariate (adjusted for gout and other terms?) rather than using them to define subgroups within which the main gout/CRC association was explored. This needs to be made more explicit in the text (either methods or results). Also, in table 3 if gout was listed in the rows in the same way as for the other covariates (rather than providing data for the columns) this would also make this clearer. Response: As suggested, we have revised Table 3 . We also revised the text in the result section: Risk and relative risk of CRC. "Although a higher CRC IRR (1.15) was observed in the gout cohort than in the non-gout cohort, the adverse effect of gout on CRC risk disappeared after potential confounders, including age, sex, residential location and urbanisation status, hypertension, diabetes, hyperlipidaemia, comorbidity score and PS, were considered and adjusted in the multivariate regression model. Cox's regression model indicated that compared with the non-gout cohort, the HR of CRC group presented no significant increase in patients with gout (HR=1.04, 95% CI=0.95-1.15). Once the Cox regression model additionally considered PS in addition to covariates listed in Table 1 , it showed HR of 1.04 (95% CI: 0.95-1.15) for the gout group (Table 3) ." (page 10, lines 12-20) Comment 9. Discussion>page 17, line 15: Ref. 38 is claimed to provide valuable data on lower rates of CRC in users of allopurinol, however, the reference provided is from a book chapter rather than research paper, the topic of which seems only vaguely related to this study question. It would be helpful to provide alternative details as to where the data from this study from Israel can be obtained. Response: This Israeli study was presented in a conference, but no detailed information can be available ("Rennert G, Almog R, Bonner JD, Rennert HS, Low M, Gruber SB. Allopurinol Use and Colorectal Cancer Risk. Abstract #C88 AACR Third Annual International Conference on Frontiers in Cancer Prevention Research, 2004, Seattle (WA), USA."). We decided to delete the text relevant to this conference paper, and added more details about the topic in discussion section." "A prospective randomised controlled double-blind trial study in 1993 indicated that allopurinol use (50 mg by mouth four times a day) prolonged survival of patients with advanced CRC 36 37 . Rajendra et al. demonstrated that high dose of allopurinol (600 mg/day) caused significant endothelial dysfunction improvement and oxidative stress reduction in subjects with stable coronary artery disease 38 . A randomised, placebo-controlled, preoperative trial demonstrated that four-week use of allopurinol (100 or 300 mg) reduced oxidative activation in colon adenomatous polyps and normal adjacent tissue in 73 subjects with colorectal adenomas 39 ." (page 16, lines 12-19) Comment 10. Discussion>General: Whilst recognition of unmeasured confounding was present in the strengths/limitations paragraph more discussion on the likely impact on the results should be provided. Which variables in the view of the authors are most likely to confound (or provide an alternative explanation for) a relationship between gout and CRC. Were these the variables adjusted for as a consequence of an a priori approach to confounder selection or were these factors which could not be adjusted for as data were not available? Response: As suggested, the Discussion section is updated and we have added the following paragraph. "In the Framingham study, a high BMI has been observed in patients with gout 23 . In addition to obesity, life style factors, including alcohol intake and smoking, were prevalent in the gout group [24] [25] [26] . Associations between these factors and CRC have been well documented in epidemiological studies 27, 28 . However, the NHI claims data provide no information on smoking habits, alcohol consumption and BMI. Failure to adjust these risk factors may have resulted in residual confounding in our study results." (page 15, lines 14-20) Comment 11. Discussion>General: As the authors indicate, this research opens up a potentially more important research question than the one addressed by this study, that being whether allopurinol may influence cancer risks, and the extent to which this risk varies for different cancers. The discussion on this could be improved by more fully providing; 1. A more complete overview of current data from cohort studies and RCTs on this topic. 2. A brief overview of key aspects to consider in the design of future studies on this topic. Response: We followed the Reviewer's comment by adding more discussion on the issue of allopurinol. In fact, in response to the comment by the Reviewer, we have conducted, based on our data, a preliminary analysis of CRC risk in relation to allopurinol. Please see Tables A and B below. We have summarized the analytical results in the Discussion section: "To further explore the relationship between allopurinol and CRC risk, we conducted a posterior analysis comparing CRC risk between patients with gout with and without prescriptions for allopurinol in 1997 and 2013. Follow-up from patients with gout and taking allopurinol started from date of allopurinol prescription, whereas follow-up of those without allopurinol medication started on the date of gout diagnosis. Analytical results indicated a weak and insignificantly inverse association between allopurinol and risk of CRC among patients with gout (HR: 0.95; CI 95%: 0.80-1.12). This posterior analysis failed to entirely exclude the possibility that allopurinol could be responsible for the null association between gout and CRC, mainly because we are unable to consider a comprehensive list of risk factors for CRC in the analysis." (page 17, lines 1-10) 2.72 (0.02-327.23) In response to the Reviewer's comment, we also provided more discussion on the putative link between allopurinol and CRC, and proposed design features for future observational studies that used real-world clinical data. "A prospective randomised controlled double-blind trial study in 1993 indicated that allopurinol use (50 mg by mouth four times a day) prolonged survival of patients with advanced CRC 36 37 . Rajendra et al. demonstrated that high dose of allopurinol (600 mg/day) caused significant endothelial dysfunction improvement and oxidative stress reduction in subjects with stable coronary artery disease 38 . A randomised, placebo-controlled, preoperative trial demonstrated that four-week use of allopurinol (100 or 300 mg) reduced oxidative activation in colon adenomatous polyps and normal adjacent tissue in 73 subjects with colorectal adenomas 39 . (page 16, lines 12-19) Nonetheless, the potential protective role of allopurinol from carcinogenesis is only limited to CRC. The clinical investigation by Chen et al. reported that allopurinol use is associated with increased risks of bladder cancer and all-cause cancers, especially for gout patients who had used allopurinol for more than 90 days 14 40 . A recent retrospective Taiwanese study suggested that medications used by patients with gout were associated with increased risk of various cancers, including leukaemia, non-Hodgkin's lymphoma, leukaemia and breast, endometrial and cervical malignancies 41 ……………Whether allopurinol plays an important role in preventing the development of CRC in patients with gout requires further and robust controlled studies. Regarding the suggested future studies: "In conclusion, our study indicated that Taiwanese patients with gout diagnosis showed no association with significantly increased risk of CRC. Future pharmaco-epidemiological studies should be conducted to specifically investigate the putative link between allopurinol/colchicine and CRC risk among patients with gout. These future observational studies should thoroughly consider potential confounders in their designs. In addition, whether a dose threshold or dose-gradient effects of allopurinol exist on the risk of CRC should also be researched in future studies. (page 17, line 20 to page 18, line 1) Comment 12. General: Whilst the manuscript was clearly legible, the standard of written English could be improved in places. I would advise a complete proof reading of the manuscript so that the standard is acceptable for an English language journal. An example is in line 18 of page 16…"gout patients are more prevalent in rural area than non-gout group". Response: We have followed the Reviewer's suggestion by sending out the manuscript for English language editorial work. The certificate of proof-reading is shown below:
Re: Response to original comment 5 (peer reviewer 4): The proportions who developed the event of interest in the 2 groups were near identical (2.04 vs. 1.98%) so I don't think this could account for a whole year difference in average follow-up. As you have highlighted this difference is not statistical, I would make table 1 more informative (by replacing P>0.05 with the actual pvalue) and remove the added text on page 8/9 re: earlier termination of follow-up time, which may mislead people.
Re: Response to original comment 6 (peer reviewer 4): Rephrase "insignificant" as "non-significant".
VERSION 2 -AUTHOR RESPONSE Response to Reviewer #4 Comments
Reviewer: 4 Reviewer Name: Matthew Grainge Institution and Country: University of Nottingham, UK Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below I believe the authors have responded favourably to the reviewer comments and the manuscript is much improved. A few remaining concerns.
Comment 1
The authors have created a post hoc propensity score which they have fitted in the final regression model. The CI associated with this term is very wide (0.13 to 24.11). I wonder if this is a consequence of fitting this term together with the component terms (e.g. specific comorbidities and urbanisation status) and thus introducing some instability in this final model. As suggested, we have added the following information to the Statistics analysis section:
Response
"We also examined the robustness of risk estimates for CRC in association with gout due to potential problem of co-linearity involving simultaneous inclusion of urbanization, co-morbidity, and PS in the regression model. The results indeed showed a sign of co-linearity between PS and hypertension/hyperlipidaemia, rendering a wide CI for the risk estimate associated with PS. However,
